Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Muscle-invasive Bladder Cancer × Genitourinary × Clear all

Phase

Status

Recruiting 2 Not yet recruiting 2 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 505 Carcinoma, Renal Cell 224 Urinary Bladder Neoplasms 146 Kidney Neoplasms 92 Neoplasm Metastasis 79 Neoplasms 78 Carcinoma, Non-Small-Cell Lung 76 Carcinoma, Transitional Cell 69 Melanoma 67 Breast Neoplasms 66 Ovarian Neoplasms 47 Lung Neoplasms 41 Colorectal Neoplasms 38 Sarcoma 32 Pancreatic Neoplasms 29 Squamous Cell Carcinoma of Head and Neck 28 Stomach Neoplasms 27 Testicular Neoplasms 24 Uterine Cervical Neoplasms 21 Triple Negative Breast Neoplasms 21 Esophageal Neoplasms 20 Non-Muscle Invasive Bladder Neoplasms 19 Carcinoma, Hepatocellular 19 Small Cell Lung Carcinoma 17 Head and Neck Neoplasms 17 Multiple Myeloma 16 Neuroblastoma 15 Colonic Neoplasms 15 Lymphoma, Non-Hodgkin 14 Brain Neoplasms 14

Interventions

tremelimumab 1 durvalumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03234153 2020-06-17

NITIMIB

Insel Gruppe AG, University Hospital Bern

Phase 2 Terminated

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡